Sak JJ, Prystupa A, Kiciński P, Luchowska-Kocot D, Kurys-Denis E, Bis-Wencel H. Leukocyte cell-derived chemotaxin-2 and fibroblast growth factor 21 in alcohol-induced liver cirrhosis. World J Hepatol 2021; 13(12): 2071-2080 [PMID: 35070009 DOI: 10.4254/wjh.v13.i12.2071]
Corresponding Author of This Article
Jarosław Jerzy Sak, MD, PhD, Academic Research, Additional Professor, Director, Chair and Department of Humanities and Social Medicine, Medical University of Lublin, ul. Chodźki 7 (Collegium Academicum), Lublin 20-093, Poland. jaroslaw.sak@umlub.pl
Research Domain of This Article
Medicine, General & Internal
Article-Type of This Article
Case Control Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Dec 27, 2021; 13(12): 2071-2080 Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.2071
Table 1 Patients’ demographics and clinical characteristics
Control group (n = 17)
Liver cirrhosis
P value
Pugh-Child A + B (n = 37)
Pugh-Child C (n = 32)
Age (yr)
43.7 ± 14.6
55.7 ± 12.1
55.9 ± 10.2
0.021
Percentage of males (%)
64.3%
73%
72.7%
0.52
Body weight (kg)
67.6 ± 8.9
73 ± 11.4
75.5 ± 12.8
0.17
Height (cm)
173 ± 5.9
174 ± 8
173 ± 7.6
0.64
Duration of alcohol abuse (yr)
-
15.7 ± 8.2
18.7 ± 8.3
0.98
Oesophageal varices (%)
-
32.4%
81.8%
< 0.0001
Encephalopathy (%)
-
32.4%
83.9%
< 0.0001
Ascites (%)
-
40.5%
90.9%
< 0.0001
Total bilirubin (mg/dL)
0.6 ± 0.3
4.6 ± 6.9
10.5 ± 9.2
< 0.0001
INR
-
1.36 ± 0.35
1.95 ± 0.56
< 0.0001
Albumin (g/dL)
-
3.1±0.8
2.4±0.4
0.0002
Total protein (g/dL)
6.3 ± 0.3
6.4 ± 1
5.9 ± 0.9
0.16
Alanine aminotransferase (U/L)
17.9 ± 6
65.3 ± 139.9
50.6 ± 87.3
0.018
Aspartate aminotransferase (U/l)
18.3 ± 7
128.1 ± 173.5
120 ± 164.7
< 0.0001
Platelets (G/L)
231.4 ± 29.8
173 ± 105.4
127.8 ± 72.3
0.0004
Mean corpuscular volume (fL)
84.8 ± 3.5
91.2 ± 9.1
95.5 ± 9
0.0002
Urea (mg/dL)
-
27.5 ± 16.1
58.2 ± 43.7
0.065
Sodium (mmol/l)
140 ± 3.3
133.8 ± 5
131.9 ± 6.7
< 0.0001
Potassium (mmol/L)
4.4 ± 0.4
3.8 ± 0.7
3.9 ± 0.8
0.019
C-reactive protein (mg/L)
2.5 ± 2.3
19.8 ± 21
32.7 ± 27.8
< 0.0001
Angiotensinogen (ng/mL)
1006.91 ± 610.49
1117.04 ± 873.69
1468.7 ± 817.33
0.22
Table 2 Levels of selected biochemical parameters according to the stage of liver cirrhosis
Control group
Liver cirrhosis
P value
Pugh-Child A + B
Pugh-Child C
LECT2 (ng/mL)
18.99 ± 5.36
11.06 ± 6.47
8.06 ± 5.74
< 0.0001
FGF-1 (pg/mL)
37.94 ± 40.4
144.77 ± 14.42
164.52 ± 169.46
0.01
FGF-21 (pg/mL)
13.52 ± 7.51
44.27 ± 64.19
45.4 ± 51.69
0.008
Table 3 Correlations between leukocyte cell-derived chemotaxin-2 and other clinical and laboratory parameters (only those statistically significant were included)